Effectiveness of Nebulized Dexmedetomidine for Treatment of Obstetric Post-Dural Puncture Headache

• Status: Completed
• Trial end date: 2021-02-28
• Target enrollment: 0
• Participant gender: Female

Summary

Postdural puncture headache (PDPH) is a common complication, following neuraxial techniques. The obstetric population is particularly prone to PDPH. Therefore, treatment of PDPH is a key issue in obstetric anesthesia.

Dexmedetomidine is a highly selective, centrally acting α2-adrenergic agonist with analgesic and anxiolytic effects. Moreover, it decreases cerebral blood flow (CBF) in humans and animals secondary to cerebrovascular vasoconstriction. It has been used via the intranasal and inhalational routes for many purposes including premedication, sedation and postoperative analgesia. Because of its desirable properties, we hypothesized that dexmedetomidine nebulization could be effective in the treatment of patients suffering from PDPH after caesarean section.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zagazig University
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Post-partum females diagnosed with PDPH after elective caesarean section under spinal anesthesia and with visual analogue score (VAS) ≥ 4 and Lybecker et al. classification score ≥2.

• Age 21- 40 years old.

• ASA I and ASA II.

• Accepted mental state of the patient.

Exclusion Criteria:

• Patient refusal.

• ASA Grade III and IV.

• Emergent caesarean section.

• Inadequate temporal window.

• Hypertensive disorders of the pregnancy.

• Atrial fibrillation.

• History of allergy to local anesthetics.

• History of chronic headache, migraine, convulsions, and cerebrovascular accident.

• Contraindication to spinal anesthesia: coagulopathy, infection at site of injection